Lijec̆nic̆ki vjesnik
-
Lijec̆nic̆ki vjesnik · Nov 2004
Clinical Trial[Rituximab in the treatment of indolent non-Hodgkin's lymphoma].
Indolent Non-Hodgkin's lymphomas (NHL) are a group of slowly progressive immune system malignancies that cannot be cured with conventional treatment. Rituximab is an anti-CD20 monoclonal antibody that has recently become a part of the standard treatment of B-cell lymphoid malignancies. Here we present our experience in 25 patients with indolent NHL treated with rituximab with or without chemotherapy. ⋯ Response and survival rates were significantly better in patients with favorable prognosis (lower IPI score). Adverse effects related to rituximab occurred in 2 patients and were mild. Our results are completely comparable to previously reported studies and show that rituximab is effective and safe for the treatment of indolent B-cell NHL.
-
Lijec̆nic̆ki vjesnik · Nov 2004
Case Reports[Out-of-hospital use of transcutaneous cardiac pacing].
Transcutaneous cardiac pacing is a non-invasive method for the treatment of serious bradycardias and asystolic cardiac arrest. Due to its simplicity this method does not require a long-lasting education. It can be quickly applied avoiding all the risks connected with the central venous cannulation. ⋯ This refers especially to the use of transcutaneous cardiac pacing in out-of-hospital medical centers. This work shows two cases of successful cardiac pacing in the patients with life threatening bradycardias under the conditions of medicine on the island. The conclusion is that the equipment for transcutaneous cardiac pacing should become a part of the standard resuscitation equipment in all our centers that are involved in the activities of emergency medicine.